Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

IRVINE, Calif., March 26 /PRNewswire-FirstCall/ -- NuRx Pharmaceutical Inc.'s (OTC Bulletin Board: NURX) next-generation rexinoid agonist, NRX4204, significantly reduced the number and size of lung tumors and lowered the total tumor volume in mouse models compared to the control group, according to a paper published in Clinical Cancer Research (2007; Vol. 13, Issue 20: 6237-6243).

In addition, the paper showed that NRX4204 caused marked tumor regression in all of the mammary tumors when used therapeutically. Rexinoids regulate cell proliferation, differentiation, and apoptosis pathways.

Entitled "A New Rexinoid, NRX4204, Prevents Carcinogenesis in Both Lung and Mammary Gland," the paper is based on a study that first evaluated the anti-inflammatory effects of NRX4204 and its growth-inhibitory properties in vitro and then measured the compound's ability to prevent and/or treat experimental lung and estrogen receptor (ER)-negative breast cancer in vivo.

"This study demonstrates that NRX4204 is exceptionally potent and not only reduces the number and size of adenocarcinomas in the lung, but it also prevents the development of mammary tumors and induces striking tumor regression in established mammary tumors," said Michael Sporn, Ph.D., professor of pharmacology and toxicology and of medicine at Dartmouth Medical School and the study's principal investigator. "For the first time, NRX4204 also showed effects as an anti-inflammatory agent in cell culture models that are highly relevant for human inflammatory diseases."

Harin Padma-Nathan, M.D., President and CEO of NuRx Pharmaceuticals said: "In this study, NRX4204 exhibited dramatic effects in the prevention of the development of lung cancer and in the prevention and treatment of breast cancer in spontaneous models. We have initiated a Phase I clinical trial and intend to pursue the development of this compound as a treatment for both lung and breast cancer. There are no rexinoid treatm
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Milliman, Inc., a ... results of its 2013 Milliman Medical Index (MMI), which ... of four receiving healthcare benefits through an employer-sponsored preferred ... this typical family in 2013 is $22,030. ... the prior year on a percentage basis was the ...
(Date:5/22/2013)... 2013  Modern Medical announced today the nationwide ... November 2012 in a test phase, ODM is ... the rising opioid abuse in the workers, compensation ... to protect employees, physicians and employers by reducing ... to provide pain relief for the injured worker.  ...
(Date:5/22/2013)... -- Pomerantz Grossman Hufford Dahlstrom ... investors of Intuitive Surgical, Inc. ("Intuitive Surgical" or the ... purchased Intuitive Surgical common stock between October 19, 2011 ... are advised to contact Robert S. Willoughby ... 237. The investigation concerns whether Intuitive Surgical ...
Breaking Medicine Technology:Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
... N.J., Sept. 23 NeoStem, Inc. (NYSE Amex: ... in the U.S. and China and Progenitor Cell Therapy, ... the cell therapy industry from licensed, state-of-the art cell ... jointly announced the signing of a  definitive merger agreement ...
... which represents the interests of the worldwide mobile communications ... Awards programme. New categories have been added to recognise ... evolving mobile ecosystem. Specifically, the GSMA will shine a ... – space for the first time. "Health ...
Cached Medicine Technology:NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 2NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 3NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 4GSMA's Global Mobile Awards To Recognise Mobile Innovation in the mHealth Sector 2
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... therapy4parents.com , hosted by Patricia O’Laughlin Psychotherapy in ... now seeing people of all ages as progression ... “Including children of all ages into parenting therapy ... Patricia O’Laughlin emphasizes. Patricia O’Laughlin Psychotherapy now specializes ...
(Date:5/22/2013)... IA (PRWEB) May 22, 2013 Diversity ... piece Handicap This! The performance promotes awareness that ... dreams. The Handicap This! performance will be held Friday, ... High School auditorium. Tickets for Handicap This! can ... This! helps audiences measure the level to which their ...
(Date:5/22/2013)... May 22, 2013 Today, Zane Benefits, ... Health Insurance Exchange . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... Zane Benefits’ website, beginning in 2014 as part of ... individuals and small businesses will become available through new ...
(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Award Presented ... Read the press release here: http://bit.ly/13DkFfk , ... was named “Information Management Product/Service of the Year” at ... March at The Colony Hotel in Palm Beach, Florida. ... virtual data room (VDR) solution that optimizes the ...
Breaking Medicine News(10 mins):Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3
... change that has come to Washington is now needed ... leader in prevention.(Logo: http://www.newscom.com/cgi-bin/prnh/20080506/NETU129LOGO )"As the ... capital, the time is ripe to bring a fresh ... Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. ...
... Inc.,(NYSE: HSP ), a leading global specialty pharmaceutical ... conference call to discuss its,fourth-quarter and full-year 2008 results and ... Central time. , The company will ... the U.S. stock market open and the conference,call. , ...
... As unemployment continues to,rise in the United States, Americans are ... what would happen if they were struck with a,serious medical ... pay for,the care? But the widely known benefit of hospice ... available to all eligible,Americans - whether they are employed or ...
... Americans who use illegal diet pills from South America ... both their health and their jobs. Physicians need to ... effects of these drugs to allow them to identify ... findings1, by Dr Pieter Cohen from the Department of ...
... 26, 2009) There is hope that the drug rasagiline ... does -- slow the progression of a devastating degenerative brain ... and function. , Now a new study looking at ... indicates that people who began the drug earlier continued to ...
... offers retailing veterans a 25% discount on the initial ... strongest and best franchise organizationPITTSBURGH, Jan. 26 Despite ... which has cost thousands of experienced retail employees their ... $21 billion industry and continues to grow at a ...
Cached Medicine News:Health News:U.S. Preventive Medicine Recommends Changing CDC Name to Centers for Disease Prevention and Control 2Health News:Hospice Care Remains a Misunderstood and Underutilized Benefit, According to In-House Hospice 2Health News:Hospice Care Remains a Misunderstood and Underutilized Benefit, According to In-House Hospice 3Health News:Caution: Lose more than weight with imported diet pills 2Health News:Patients starting Parkinson's drug rasagiline earlier do better 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 3
... the ureter to be dilated immediately below ... base of the balloon allows fluoroscopic confirmation ... sterile in peel-open packages. Intended for one-time ... Straight Safety Wire Guide [.038 inch (0.97 ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Small 6.9 Fr Diameter with Two Large ... USA Series MICRO-6 Semi-Rigid Ureteroscope is the ... for diagnostic and therapeutic procedures. The ACMI ... time for procedures with minimal or no ...
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
Medicine Products: